← Back to patent-cliff list
RDX-013
Tier C — Watch / tradeRDX-013
Ardelyx Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Potassium channel
Indications (approved)：Hyperkalaemia
Regional status
US
Phase II
2021-01-11
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RDX-013?
Approved indications include: Hyperkalaemia.
When does the RDX-013 patent expire?
No public expiry year is available for RDX-013 yet; this page updates once verified.
How do I get a quote for RDX-013 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06